Immunovant (Immunovant) Cash, Cash Equivalents, Marketable Securities : $690.94 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Immunovant Cash, Cash Equivalents, Marketable Securities?

Immunovant's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($329.96 Mil) to Sep. 2023 ($269.93 Mil) but then increased from Sep. 2023 ($269.93 Mil) to Dec. 2023 ($690.94 Mil).

Immunovant's annual cash, cash equivalents, marketable securities increased from Mar. 2021 ($400.15 Mil) to Mar. 2022 ($493.82 Mil) but then declined from Mar. 2022 ($493.82 Mil) to Mar. 2023 ($376.53 Mil).

Immunovant Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Immunovant's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant Cash, Cash Equivalents, Marketable Securities Chart

Immunovant Annual Data

Trend

Dec18

Mar20

Mar21

Mar22

Mar23

Cash, Cash Equivalents, Marketable Securities

0.33

100.57

400.15

493.82

376.53

Immunovant Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															432.61	376.53	329.96	269.93	690.94

Immunovant Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Immunovant (NAS:IMVT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Immunovant Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Immunovant's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovant (Immunovant) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

320 West 37th Street, 6th Floor, New York, NY, USA, 10018

Website

https://www.immunovant.com

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Executives

William L. Macias	officer: Chief Medical Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Eva Renee Barnett	officer: Chief Financial Officer	C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Julia G. Butchko	officer: Chief Dev. & Tech. Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Peter Salzmann	director, officer: Chief Executive Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mark S. Levine	officer: Chief Legal Officer	1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Jay S Stout	officer: Chief Technology Officer	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Frank Torti	director	2855 SAND HILL ROAD, MENLO PARK CA 94025
Douglas J. Hughes	director	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Rita Jain	officer: Chief Medical Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott	officer: Chief Scientific Officer	320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018